

# Fact Sheet

**Media Relations:** Mike Laffin, 724.514.1968, michael.laffin@mylan.com

**Investor Relations:** Kris King, 724.514.1813, kris.king@mylan.com

**Government Relations:** David Rice, 724.514.1841, david.rice@mylan.com

[www.mylan.com](http://www.mylan.com)

## ▼ CORPORATE PROFILE

Mylan is one of the world's leading generics and specialty pharmaceutical companies, providing products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline. With approximately 15,500 employees, Mylan has attained leading positions in key international markets through its wide array of dosage forms and delivery systems, significant manufacturing capacity, global commercial scale and a committed focus on quality and customer service. The company ranks among the top five generics companies in several international markets and is the largest U.S.-based generics manufacturer in the world.

Through its subsidiary Matrix Laboratories, Mylan has direct access to one of the world's largest active pharmaceutical ingredient (API) manufacturers. This relationship makes Mylan one of only two global generics companies with a comprehensive, vertically integrated supply chain. Matrix also is one of the world's largest producers of API used to make generic antiretroviral (ARV) therapies for the treatment of HIV/AIDS.

Additionally, Mylan operates a fully integrated specialty pharmaceutical business, Dey Pharma, which produces innovative medicinal therapies, including EpiPen® Auto-Injector and Perforomist® Inhalation Solution.



## ▼ OUR MISSION

As a leading provider of generic and specialty pharmaceuticals, Mylan maintains one of the industry's largest commercial footprints and a network that spans the globe. Operating this network seamlessly – across all of our businesses – is our highest priority. Our scope and depth enable us to offer our customers a comprehensive portfolio of innovative and affordable quality products backed by the industry's highest standards for service, delivery and reliability. Because at Mylan, anything less isn't good enough.

## ▼ OUR VISION

We aspire to relentlessly improve product innovation, customer service and global operational excellence to ensure Mylan's position as one of the world's leading providers of generic and specialty pharmaceuticals. We will continue to address patients' unmet needs and provide them with access to our products virtually anywhere in the world. Because of this unwavering commitment, we believe we can unlock additional value for patients, customers, shareholders and our employees, without compromising the integrity of our enterprise, and become the most efficient global generics and specialty pharmaceutical company in the industry.

## ▼ MARKET INFORMATION

**Exchange:** The NASDAQ Stock Market ▶ **Symbol:** MYL ▶ **Member:** S&P 500

## ▼ EXECUTIVE MANAGEMENT TEAM

**Robert J. Coury**  
Chairman and CEO

**Heather Bresch**  
President

**John D. Sheehan**  
Chief Financial Officer

**Rajiv Malik**  
Chief Operating Officer

## ▼ DIVISION HEADS

**Didier Barret**  
President, Europe, the Middle East and Africa

**Harry A. Korman**  
President, North America


**Carolyn Myers, Ph.D.**  
President, Dey Pharma

**S. Srinivasan**  
Managing Director and CEO  
Matrix Laboratories



1500 Corporate Drive  
Canonsburg, PA 15317  
Telephone: 724.514.1800  
e-mail: [GPA@mylan.com](mailto:GPA@mylan.com)

▼ **2009 ADJUSTED REVENUES<sup>(1)</sup> = \$5,062 million**



▼ **FINANCIAL HIGHLIGHTS** (in millions)

as of and for the year ended Dec. 31, 2009	
Adjusted revenues <sup>(1)</sup>	\$5,062
Research and development	275
Earnings from operations	523
Total assets	10,802
Long-term debt <sup>(2)</sup>	4,763
Shareholders' equity	3,145

<sup>(1)</sup> Represents a "non-GAAP financial measure." See quarterly earnings press releases at [www.mylan.com](http://www.mylan.com) for GAAP to non-GAAP reconciliations.

<sup>(2)</sup> Represents total long-term debt, excluding discounts and conversion feature.

▼ **KEY MILESTONES**

**1961** ▼

Mylan founded in White Sulphur Springs, W. Va. as a drug distributor.

**1966** ▼

Mylan manufactures first product – Penicillin G.

**1973** ▼

Mylan becomes a public company.

**1984** ▼

Mylan becomes first generics company to patent a new drug – Maxzide®.

**2002** ▼

Mylan surpasses \$1 billion in sales.

**2007** ▼

Mylan buys a majority interest in Matrix Laboratories.

**2007** ▼

Mylan acquires the generics business of Merck KGaA.

**2009** ▼

Mylan surpasses \$5 billion in sales.

▼ **FAST FACTS**

- ▶ World's third largest generics and specialty pharmaceutical company
- ▶ Largest global generic pharmaceuticals company headquartered in the U.S.
- ▶ One out of every 12 prescriptions dispensed in the U.S. – brand name or generic – is a Mylan product.
- ▶ Approximately 15,500 employees around the world
- ▶ Global manufacturing capacity of more than 45 billion doses (includes a U.S. capacity of 35 billion doses from one of largest pharmaceutical manufacturing facilities in the world, located in Morgantown, W.Va.)
- ▶ One of only two global generics companies with true vertical integration
- ▶ A Fortune 500 company
- ▶ Sells products in more than 140 countries and territories
- ▶ One of industry's broadest and highest quality product portfolios, with more than 900 separate products
- ▶ Top-five positions in Australia, Belgium, Canada, France, Ireland, Italy, Japan, the Netherlands, New Zealand, Portugal, Spain, Sweden, the U.K. and the U.S.
- ▶ Has more than 140 ANDAs pending FDA approval, 40 of which represent "first-to-file" opportunities (June 2010)
- ▶ Year after year, customers place Mylan at the top of the class in service and support. For instance, Mylan received Walmart's 2008 Health and Wellness Supplier of the Year award.
- ▶ No.1 provider of unit-dose generics in the U.S.
- ▶ Dey, Mylan's specialty business, focuses on respiratory, allergy and psychiatric therapies. Its flagship product is EpiPen Auto-Injector, which treats anaphylaxis; the product had a 96% share of the U.S. market and a 93% share of the world market at the end of 2009.
- ▶ Matrix, a Mylan subsidiary, is one of the world's largest manufacturers of API and one of the largest manufacturers of API used in the formulation of ARV medications that treat HIV/AIDS.
- ▶ Approximately 30% of people living with HIV/AIDS in the developing world who are receiving treatment depend on Matrix API or finished dosage ARV products.



# Delivering good health Around the corner and across the world

Mylan organizes its commercial operations around its global generics business and its specialty business, Dey. Mylan further organizes its generics business by geographic regions: North America; Europe, the Middle East and Africa; and Asia Pacific.

Through the acquisitions and successful integration of Matrix and the former Merck Generics business, Mylan has transformed itself from the third largest generics pharmaceutical company in the U.S. to the third largest generics and specialty pharmaceutical company in the world. As a result, Mylan now has the scale and resources needed for ongoing success, such as a global commercial footprint, an

extensive product portfolio, deep research and development capabilities, expanded manufacturing capacity, and operations that are integrated vertically and horizontally. Mylan's employees now are leveraging these assets to achieve the company's next major goal: becoming the industry's most efficient company.

## ▶ GLOBAL MARKET LEADERSHIP

Mylan enjoys leadership positions in several markets.

**No. 1** Australia, France, Italy and New Zealand

**No. 2** U.S.

**Top 5** Belgium, Canada, Ireland, Japan, the Netherlands, Portugal, Spain, Sweden, and the U.K.

*IMS Health/Mylan management estimates*

## Our Values Define Our Culture

**Innovation:** We are unconventional, visionary and bold. We "connect the dots" others overlook. We see possibilities and bring them to life. We love to challenge the status quo and introduce new and better ways to help people everywhere enjoy a higher quality of life. Having the courage to be a force for constructive change is in our DNA.

**Integrity:** Doing what's right is sacred to us. We behave responsibly, even when nobody's looking. We set high standards from which we never back down. This uncompromising ethical stance helps to keep our products pure, our workers safe and the environment clean.

**Reliability:** Dependable. Reliable. Call it what you will, we've made it a habit. We strive to be there through thick and thin, rain or shine, delivering on every promise, every time. That's why people around the corner and across the world count on Mylan.

**Service:** We understand that "it's not about us" – it's about helping others – and we believe there's no situation we can't handle. We would do whatever it takes, work round the clock, cross any river and spare no effort – all to meet someone's need. We wrap our high quality products in high quality service.

**Teamwork:** Together, we can run faster, reach higher and achieve more than any one of us can alone. We relish opportunities to collaborate because it's invigorating, enlightening and powerful. When we join forces and plow through boundaries, we move mountains.

